Core Insights - Pacira BioSciences reported solid execution in its corporate, clinical, and commercial initiatives, advancing its 5x30 growth strategy aimed at accelerating topline growth and transitioning into an innovative biopharmaceutical organization [4][5] Financial Highlights - Total revenues for Q2 2025 were $181.1 million, an increase from $178.0 million in Q2 2024 [11] - Net product sales included $142.9 million for EXPAREL, $31.3 million for ZILRETTA, and $5.6 million for iovera° [6] - The company reported a net loss of $4.8 million, or $0.11 per share, compared to a net income of $18.9 million, or $0.41 per share in Q2 2024 [11] - Adjusted EBITDA for Q2 2025 was $54.3 million, down from $62.1 million in Q2 2024 [11] Business Developments - The company surpassed 50% enrollment in its Phase 2 ASCEND study of PCRX-201 for knee osteoarthritis, with completion expected by the end of 2025 [7] - A new $300 million revolving credit facility was established to enhance liquidity and financial flexibility [7] - A co-promotion agreement with Johnson & Johnson MedTech aims to expand ZILRETTA's market reach [7] - Manufacturing efficiencies from large-scale EXPAREL production are expected to improve gross margins and inventory management [7] Legal and Patent Developments - A favorable court ruling resulted in a $28.3 million payment from the Research and Development Foundation [8] - The company secured additional patents for EXPAREL, extending exclusivity through 2041 and 2044 [8] Financial Guidance - The company updated its full-year 2025 revenue guidance to a range of $730 million to $750 million, while increasing non-GAAP gross margin guidance to 78-80% [19]

Company Overview - PharmaCorp Rx Inc. operates three PharmaChoice bannered pharmacies in Canada and plans to acquire more as they become available [2] - The company has a strategic alliance agreement with PharmaChoice Canada to facilitate these acquisitions [2] - PharmaCorp also intends to acquire independently owned non-PharmaChoice Canada bannered pharmacies and operate them under the PharmaChoice Canada banner [2] Recent Developments - PharmaCorp has voluntarily filed an Annual Information Form (AIF) for the year ended December 31, 2024, which is available on its website and SEDAR+ profile [1]

Core Viewpoint - Pacira BioSciences, Inc. is set to report its second quarter financial results on August 5, 2025, and will host a live conference call and webcast following the release [1]. Company Overview - Pacira specializes in innovative, non-opioid pain therapies aimed at transforming patient lives [3]. - The company has three commercial-stage non-opioid treatments: - EXPAREL, a long-acting local analgesic for various postsurgical pain management applications [3]. - ZILRETTA, an extended-release injection for osteoarthritis knee pain management [3]. - ioveraº, a handheld device providing immediate, long-acting, drug-free pain control through cold temperature [3]. - Pacira is also developing PCRX-201, a novel gene therapy targeting prevalent diseases like osteoarthritis [3].

Core Insights - Pacira BioSciences has announced a strategic collaboration with Johnson & Johnson MedTech to enhance the market reach of ZILRETTA, an extended-release treatment for osteoarthritis knee pain, by leveraging Johnson & Johnson's specialized sales force [1][2] - The partnership aims to significantly increase ZILRETTA sales calls and expand patient access, targeting a substantial portion of the seven million intra-articular knee injections administered annually in the U.S. [1][3] Company Overview - Pacira BioSciences specializes in innovative, non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and iovera° [4] - ZILRETTA is the first and only extended-release intra-articular therapy approved by the FDA for osteoarthritis-related knee pain, utilizing proprietary microsphere technology for prolonged pain relief [5] Strategic Collaboration Details - The collaboration with Johnson & Johnson MedTech will enhance promotional efforts and extend ZILRETTA's reach beyond orthopedic practices into other specialties such as sports medicine, pain management, and rheumatology [3] - This partnership is part of Pacira's "5x30 strategy," which focuses on leveraging targeted collaborations to drive growth and improve patient outcomes with non-opioid treatments [2]

Core Viewpoint - A lawsuit is pending against Pacira BioSciences, Inc. for alleged violations of securities laws related to misleading statements about patent protections for its product Exparel, which is critical for the company's revenue growth [2]. Group 1: Lawsuit Details - An investor filed a lawsuit on January 13, 2025, claiming that Pacira made false statements regarding the patent protections for Exparel, which accounts for approximately 80% of the company's revenue [2]. - The lawsuit alleges that Pacira misrepresented the strength of the '495 patent, which was invalidated in a separate case, leading to concerns that generic competition could arise during the patent's life [2]. Group 2: Investor Information - Shareholders who purchased Pacira BioSciences, Inc. shares prior to August 2023 and continue to hold them are encouraged to contact the Shareholders Foundation for options related to the lawsuit [1][3].

Financial Performance & Growth Strategy - Pacira reported $701 million in revenue in 2024[10] - The company aims for double-digit compounded annual growth rate[15, 18] - Pacira anticipates a 5-percentage point gross margin improvement over 2024[15, 18] - First quarter of 2025 (1Q25) total revenue reached $169 million, with EXPAREL contributing $137 million, ZILRETTA $23 million, and iovera° $5 million[109] - Non-GAAP gross margins for 1Q25 were 81%, and adjusted EBITDA was $44 million[109] - Pacira's cash and investments exceeded $493 million as of March 31, 2025[109] Product Portfolio & Pipeline - Pacira has treated over 16 million patients with its three best-in-class products[10] - The company is expanding its clinical pipeline with 5 novel programs in development[15, 18] - Pacira is establishing 5 partnerships, including pipeline and commercial agreements[15, 18] PCRX-201 & Osteoarthritis (OA) Treatment - The global OA injectables market is projected to grow at a CAGR of 682% from 2024 to 2030[86] - PCRX-201 demonstrated that over 70% of patients saw a greater than 50% improvement in pain and stiffness vs baseline at week 16 and 78[75]

Summary of PharmaCorp Rx Inc. News Core Viewpoint PharmaCorp Rx Inc. has granted stock options to its directors, officers, employees, and consultants, with specific terms and conditions, while relying on exemptions from formal valuation and minority approval requirements under applicable regulations. Group 1: Stock Options Grant - PharmaCorp has granted a total of 827,603 options to purchase common shares at an exercise price of $0.48, expiring on July 1, 2035, pending approval from the TSX Venture Exchange [1] - The company utilized section 5.5(b) of Multilateral Instrument 61-101 to exempt the formal valuation requirements, as its common shares are only listed on the TSXV [2] - The exemption from minority approval requirements was based on section 5.7(a) of MI 61-101, as the fair market value of the options granted did not exceed 25% of the Corporation's market capitalization [2] Group 2: Company Operations - PharmaCorp operates three PharmaChoice bannered pharmacies in Canada and plans to acquire more as they become available, in line with its strategic alliance with PharmaChoice Canada [3] - The company also intends to acquire independently owned pharmacies not affiliated with PharmaChoice Canada and will operate them under the PharmaChoice Canada banner [3] - PharmaCorp shares are traded on the TSX Venture Exchange under the symbol PCRX [3]

Core Points - PharmaCorp RX Inc. has agreed to acquire a 100% interest in a PharmaChoice Canada bannered pharmacy business for a purchase price of $2,400,000, expected to close around July 31, 2025 [1][2] - The acquisition will be funded using cash on hand and is subject to customary adjustments and a net asset value adjustment as of the closing date [1] - The company currently operates three PharmaChoice bannered pharmacies and plans to continue acquiring more as part of its strategic alliance with PharmaChoice Canada [2] Company Strategy - The acquisition reflects PharmaCorp's strategic alliance with PharmaChoice Canada and its disciplined acquisition strategy [2] - The company sees strong opportunities for growth and intends to remain active in pursuing further acquisitions in the coming months [2] - PharmaCorp will also consider acquiring independently owned non-PharmaChoice Canada bannered pharmacies and operate them under the PharmaChoice Canada banner [2]

Company Overview - Pacira BioSciences, Inc. (PCRX) is currently experiencing significant activity in the options market, particularly with the January 16, 2026 $2.5 Call option showing high implied volatility, indicating potential for a major price movement [1] - The company holds a Zacks Rank of 3 (Hold) within the Medical - Biomedical and Genetics industry, which is positioned in the top 36% of the Zacks Industry Rank [3] Analyst Sentiment - Over the past 60 days, there has been a mixed sentiment among analysts regarding earnings estimates; one analyst has increased their estimate while three have decreased theirs, resulting in a slight decline in the Zacks Consensus Estimate from 74 cents to 73 cents per share for the current quarter [3] Options Market Insights - The high implied volatility surrounding Pacira BioSciences suggests that options traders are anticipating a significant price movement, which could be indicative of an upcoming event that may lead to either a rally or a sell-off [2][4] - Seasoned options traders often seek to capitalize on high implied volatility by selling premium, aiming for the underlying stock to not move as much as expected by expiration [4]

Core Insights - Pacira BioSciences, Inc. is focusing on non-opioid pain therapies to improve patient outcomes and reduce opioid dependency [1][4] - The film "The Next Frontier: Mark & Leah's Story" showcases the personal journey of Mark Allen, who overcame opioid dependency through non-opioid treatments [2][3] - The opioid crisis remains a significant public health issue, with chronic pain affecting approximately 82 million Americans and costing the U.S. up to $635 billion annually [4] Company Overview - Pacira offers three commercial-stage non-opioid treatments: EXPAREL, ZILRETTA, and iovera°, aimed at managing pain without opioids [5] - EXPAREL is a long-acting local analgesic approved for various pain management applications, while ZILRETTA is for osteoarthritis knee pain, and iovera° provides drug-free pain control [5] - The company is also developing PCRX-201, a gene therapy targeting prevalent diseases like osteoarthritis [5] Industry Context - The U.S. experienced approximately 80,391 drug overdose deaths in 2024, with opioid-related deaths decreasing to 54,743, indicating a need for alternative pain management solutions [4] - Despite the decline in opioid-related deaths, the overall opioid crisis continues to have a severe impact on public health [4] - Investment in novel pain treatments has decreased, highlighting the urgent need for innovative non-opioid therapies [4]